Our M&A lawyers are among the most experienced and effective in the world. We represent many of the world's largest publicly traded and privately held companies, as well as leading private equity firms on their most important mergers, acquisitions and takeover transactions.
GSK Acquires Elsie Biotechnologies
- Client News
- May 31, 2024
Paul, Weiss advised GSK plc in its up-to-$50 million acquisition of Elsie Biotechnologies, a San Diego-based private biotechnology company dedicated to unlocking the full potential of oligonucleotide therapeutics. Oligonucleotides have a unique ability to modulate gene expression, which gives them the potential to address hard-to-treat diseases with high unmet need.
The acquisition allows GSK to integrate Elsie’s oligonucleotide discovery, synthesis and delivery technologies to enhance GSK’s platform research and development capabilities. GSK is currently advancing oligonucleotide therapeutics in chronic hepatitis B and steatotic liver disease, among other therapeutic areas.
The Paul, Weiss team was led by corporate partners Benjamin Goodchild and Krishna Veeraraghavan, and includes executive compensation partners Jean McLoughlin and Ron Aizen, and counsel Cindy Akard; intellectual property partner Jonathan Ashtor; tax partner Brian Krause; litigation partners Geoffrey Chepiga and Joshua Soven, and counsel Steven Herzog and Pietro Signoracci; real estate partner Peter Fisch; restructuring partner Joseph Graham; and antitrust partner Marta Kelly.